A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
- Status
- active
- Phase
- Phase 2
- Institution
- Cybin IRL Limited
- Principal investigator
- Amir Inamdar, MBBS, DNB, MFPM
- Start date
- 2024-05-10
- End date
- 2026-09-01
- Registry ID
- NCT06051721
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.